Huami Corp Invests $5 Million in Hyperfine Research D Round

February 10, 2021

Huami Corp. announced that it has invested $5 million in Hyperfine Research’s D round of funding, which closed on February 3, 2021. Funds to support the accelerated application of disruptive MRI technology.

Huami Corporate mission is to connect health with technology, developing both consumer and industrial health technologies. The company believes its miniaturization engineering expertise dovetails with efforts to miniaturize medical imaging technology which can disrupt the locations, applications, and costs of medical imaging.

Hyperfine Research is pioneering MRI imaging with its portable Swoop system, which received FDA 510(K) clearance in August of 2020.

“In the same way that new depth and granularity of data from wearable devices has changed health population management, we see the miniaturization of imaging technology changing the places and speed at which clinicians can evaluate patients,” said Huami’s chief operating officer, Mike Yeung. “We are excited to participate with Hyperfine in support of their mission.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy